|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
Neotope Biosciences
|
|
gptkbp:clinicalTrials
|
gptkb:ALZ-801
Phase 2
Phase 3
biopharmaceutical company
PRX002
|
|
gptkbp:collaborations
|
gptkb:Harvard_University
gptkb:University_of_California,_San_Francisco
multiple academic institutions
|
|
gptkbp:employeeCount
|
over 100
|
|
gptkbp:focus
|
neurodegenerative diseases
|
|
gptkbp:founded
|
2012
|
|
gptkbp:founder
|
gptkb:Christoph_Westphal
|
|
gptkbp:headquarters
|
gptkb:South_San_Francisco,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Prothena Biosciences
|
|
gptkbp:investmentFocus
|
gptkb:New_Enterprise_Associates
gptkb:Sofinnova_Ventures
gptkb:Frazier_Healthcare_Partners
2013
OrbiMed Advisors
|
|
gptkbp:is_aimed_at
|
Alzheimer's disease
Amyloidosis
Parkinson's disease
|
|
gptkbp:leadership
|
experienced management team
|
|
gptkbp:leads
|
gptkb:ALZ-801
PRX002
|
|
gptkbp:market
|
approximately $500 million
|
|
gptkbp:mission
|
transforming the lives of patients
|
|
gptkbp:partnerships
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:patentCitation
|
numerous patents
|
|
gptkbp:platforms
|
monoclonal antibodies
therapeutic proteins
|
|
gptkbp:publications
|
over 100
|
|
gptkbp:regulatoryCompliance
|
gptkb:FDA
EMA
|
|
gptkbp:research_areas
|
oncology
cardiovascular diseases
immunology
|
|
gptkbp:research_focus
|
protein misfolding
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
PRTA
|
|
gptkbp:vision
|
pioneering new therapies
|